Results 181 to 190 of about 2,565,077 (232)

PI-RADSv2.1 combined with PSA density for optimizing prostate biopsy decisions: a retrospective analysis. [PDF]

Front Oncol
Li Y, Wang S, Wang J, Qi X, Liu T, He X, Zhang Y, Zhu Y, Zeng Y.   +8 more
europepmc   +1 more source

Natural History of PI‐RADS 3 Lesions on Serial Prostate mpMRI

The Prostate, EarlyView.
ABSTRACT Objective PI‐RADS 3 lesions on prostate multiparametric MRI (mpMRI) are indeterminate findings with debated management. We evaluated their radiologic evolution on follow‐up mpMRI and correlated imaging changes with biopsy outcomes. Methods We retrospectively identified 166 men with at least one PI‐RADS 3 lesion on initial mpMRI and at least ...
Tomer Bashi, Yanai Rubinstein, Adi Kidron, Ron Marom, Yuval Rand, Meitar Atias, Sophie Barnes, Ibrahim Fahoum, Gal Keren‐Paz, Mario Sofer, Ofer Yossepowitch, Snir Dekalo, Avi Beri, Roy Mano   +13 more
wiley   +1 more source

GenProb‐PCSM: A Simplified Weighted Germline Score for Prostate Cancer‐Specific Mortality

The Prostate, EarlyView.
ABSTRACT Background We previously developed a tier‐based germline classification using the National Comprehensive Cancer Network (NCCN)‐recommended DNA damage repair (DDR) genes and KLK3 I179T to predict prostate cancer (PCa)‐specific mortality (PCSM).
Jun Wei, Zhuqing Shi, Lucy Lu, John Wang, Julian Xu, Ashley J. Mulford, Huy Tran, Annabelle Ashworth, S. Lilly Zheng, Alan R. Sanders, William B. Issacs, Jun Luo, Brian Helfand, Jim Lu, Jianfeng Xu   +14 more
wiley   +1 more source

Biproximate ellipsoid formula with transrectal ultrasound: a superior method for PSA density in gray zone prostate cancer detection. [PDF]

Discov Oncol
Wang X, Sun J, Xu D, Zhu H.
europepmc   +1 more source

PSA-GNN: An augmented GNN framework with priori subgraph knowledge

PSA-GNN: An augmented GNN framework with priori subgraph ...
G Xue (13400385), M Zhong (13374294), T Qian (13458459), Jianxin Li (13075998)   +3 more
core  

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

The Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal, Gurcan Erbay, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler   +4 more
wiley   +1 more source

A nomogram using transition zone PSA density for detecting clinically significant prostate cancer in PI-RADS 3 lesions. [PDF]

Sci Rep
Wang C, Han J, Zhu W, Zheng B, Qiu Y.
europepmc   +1 more source

Evaluating larvicide performance against Culicoides sonorensis in semi‐field conditions

Pest Management Science, EarlyView.
This study evaluated the efficacy of larvicide products against Culicoides sonorensis populations under controlled semi‐field conditions. Larvicide efficacy against C. sonorensis declined over time, in different environmental conditions. In particular, precipitation and habitat disturbance influenced residual performance. Abstract BACKGROUND Culicoides
Destiny Cuellar, Robert Ewing, Dustin A Swanson, Isik Unlu, Kaz Surowiec, Kevin A Caillouet, Joseph R McMillan, Lee W Cohnstaedt, Corey L Brelsfoard   +8 more
wiley   +1 more source

Evaluating Prostate-Specific Antigen (PSA) Density Thresholds for Detecting Clinically Significant Prostate Cancer in Prostate Imaging Reporting and Data System (PI-RADS) 3 Lesions: A Retrospective Cohort Study. [PDF]

Cureus
Nazir MA, Scobie M, Balasubaramaniam V, Agarwal A, Kailasa A, Kannan S, Alexandrou K, Thangavelu M, Donev K.   +8 more
europepmc   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source